Bipartisan Michigan lawmakers unveil a bill subjecting US-China biotech deals to outbound investment screening, citing national security risks.
Rep. John Moolenaar (R-MI) (Lenin Nolly/Sipa USA/Sipa via AP Images)
June 2, 2026 08:00 AM EDT
DealsChinaPharmaFDA+
Exclusive: Bipartisan group of lawmakers unveil new bill to restrict China biotech
Max Bayer
If enacted, BINSA would give lawmakers the right to monitor and restrict American companies from signing biotech and…
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing buyers and sellers to rethink…
BINSA, a bipartisan bill restricting US biotech deals with Chinese firms, is in limbo after failing to advance via the House…
They're laying the groundwork for legislation and regulation to counter Chinese biopharma companies.
Senate BINSA bill by Slotkin & Ricketts targets biotech/pharma deals with China, mirroring House bill amid fierce industry…
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic…
